Sensei Biotherapeutics reported a net loss of $170.2 million, or $131.45 per share, for the quarter ended March 31, 2026, reflecting one-time acquired IPR&D charges related to the Faeth transaction. The company held $202.8 million in cash, cash equivalents and marketable securities as of March 31, 2026, after completing the Faeth acquisition and a $200 million private placement. Sensei said it has advanced PIKTOR into a Phase 1b/2 breast cancer trial and expects topline Phase 2 endometrial cancer data in the second half of 2026.

Financial Highlights

• Net loss: $170.2 million for Q1 2026, or $131.45 per basic and diluted share.
• R&D expenses: $17.957 million for Q1 2026 (compared with $3.725 million in Q1 2025).
• G&A expenses: $19.713 million for Q1 2026 (compared with $3.549 million in Q1 2025).
• Acquired in-process R&D expense: $132.957 million recorded in Q1 2026 related to the Faeth acquisition.
• Cash, cash equivalents and marketable securities: $202.8 million as of March 31, 2026 (vs. $21.2 million as of December 31, 2025).

Business Highlights

• Completed acquisition of Faeth Therapeutics and concurrent $200 million private placement to fund development of acquired programs.
• PIKTOR (combination of serabelisib and sapanisertib), now the lead program, is an all-oral multi-node PI3K-alpha / mTORC1/2 inhibitor advanced through the Faeth transaction.
• First patient dosed in April 2026 in the Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer (Study FTH-PIK-101); interim data expected in 2027.
• Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) is on track to report topline data in the second half of 2026.
• Continuing Phase 1/2 trial of solnerstotug (VISTA inhibitor) in patients with advanced solid tumors.

Original SEC Filing: Sensei Biotherapeutics, Inc. [ SNSE ] - 8-K - May. 15, 2026